Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7

1.

Safety and efficacy of pitolisant on cataplexy in patients with narcolepsy: a randomised, double-blind, placebo-controlled trial.

Szakacs Z, Dauvilliers Y, Mikhaylov V, Poverennova I, Krylov S, Jankovic S, Sonka K, Lehert P, Lecomte I, Lecomte JM, Schwartz JC; HARMONY-CTP study group.

Lancet Neurol. 2017 Mar;16(3):200-207. doi: 10.1016/S1474-4422(16)30333-7. Epub 2017 Jan 25.

PMID:
28129985
2.

Exploratory Phase II Trial to Evaluate the Safety and the Antiepileptic Effect of Pitolisant (BF2.649) in Refractory Partial Seizures, Given as Adjunctive Treatment During 3 Months.

Collart Dutilleul P, Ryvlin P, Kahane P, Vercueil L, Semah F, Biraben A, Schwartz JC, De Seze J, Hirsch E, Collongues N.

Clin Neuropharmacol. 2016 Jul-Aug;39(4):188-93. doi: 10.1097/WNF.0000000000000159.

PMID:
27223666
3.

Can an early phase clinical pharmacology study replace a thorough QT study? Experience with a novel H3-receptor antagonist/inverse agonist.

Shah RR, Maison-Blanche P, Robert P, Denis E, Duvauchelle T.

Eur J Clin Pharmacol. 2016 May;72(5):533-43. doi: 10.1007/s00228-016-2023-3. Epub 2016 Feb 16.

PMID:
26879827
4.

Comparing Treatment Effect Measurements in Narcolepsy: The Sustained Attention to Response Task, Epworth Sleepiness Scale and Maintenance of Wakefulness Test.

van der Heide A, van Schie MK, Lammers GJ, Dauvilliers Y, Arnulf I, Mayer G, Bassetti CL, Ding CL, Lehert P, van Dijk JG.

Sleep. 2015 Jul 1;38(7):1051-8. doi: 10.5665/sleep.4810.

5.

Pitolisant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomised trial.

Dauvilliers Y, Bassetti C, Lammers GJ, Arnulf I, Mayer G, Rodenbeck A, Lehert P, Ding CL, Lecomte JM, Schwartz JC; HARMONY I study group.

Lancet Neurol. 2013 Nov;12(11):1068-75. doi: 10.1016/S1474-4422(13)70225-4. Epub 2013 Oct 7.

PMID:
24107292
6.

Efficacy of the histamine 3 receptor (H3R) antagonist pitolisant (formerly known as tiprolisant; BF2.649) in epilepsy: dose-dependent effects in the human photosensitivity model.

Kasteleijn-Nolst Trenité D, Parain D, Genton P, Masnou P, Schwartz JC, Hirsch E.

Epilepsy Behav. 2013 Jul;28(1):66-70. doi: 10.1016/j.yebeh.2013.03.018. Epub 2013 May 8.

PMID:
23665640
7.

An inverse agonist of the histamine H(3) receptor improves wakefulness in narcolepsy: studies in orexin-/- mice and patients.

Lin JS, Dauvilliers Y, Arnulf I, Bastuji H, Anaclet C, Parmentier R, Kocher L, Yanagisawa M, Lehert P, Ligneau X, Perrin D, Robert P, Roux M, Lecomte JM, Schwartz JC.

Neurobiol Dis. 2008 Apr;30(1):74-83. doi: 10.1016/j.nbd.2007.12.003. Epub 2007 Dec 27.

PMID:
18295497

Supplemental Content

Loading ...
Support Center